Clinical trial NCT00822159: Influence of Bone Strength Measured by DensiProbe on Bone Related Fixation Failure
Official title: Prospective Multicenter Cohort Study to Evaluate the Influence of Bone Strength Measured by DensiProbe Hip on Bone Related Fixation Failure in Patients With Hip Fractures Undergoing DHS Surgical Treatment.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Femoral Fractures
Hip Fractures
Osteoporosis
Bone Density
Keywords: Fixation failure
Bone strength
DensiProbe
Lead sponsor: AO Innovation Translation Center
Sponsor class: OTHER
First posted: 2009-01-14
Enrollment: 198
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Hip fractures mostly occur in elderly people with low bone strength. Bone strength is determined by bone mineral density (BMD), bone turnover, microarchitectural and geometrical properties of the bone. Dual energy x-ray absorptiometry (DXA) is the standard technique to measure BMD. However, BMD just provides information regarding the quantity of mineral in bone, which is only one component of bone strength. To date there is no reliable method to assess bone strength in vivo. Therefore, a method to assess bone strength beyond BMD would provide additional information regarding the patients' risk of bone related fixation failure after fracture fixation.

DensiProbe is a new diagnostic device that was developed for intra-operative assessment of mechanical stability of the bone in the proximal femur. It consists of a drill bit like tool and an electronic system to measure the peak torque to break-away of trabecular bone in the femoral head of patients undergoing DHS surgical treatment. In a cadaver study comparing bone mineral density measured by quantitative computed tomography with bone strength measured by DensiProbe a high correlation between these two parameters could be shown. In a clinical pilot study a significant correlation between DensiProbe measurements and BMD measured by DXA at the femoral neck in patients with hip fractures could be shown. However, no perfect correlation was expected because DensiProbe measures bone strength, which is only partly caused by BMD.

Bone related fixation failure, such as secondary loss of reduction, is influenced by bone strength, bone mineral density, fracture type, fracture reduction and primary positioning of the implant. The predictive value of DensiProbe measurements for secondary loss of reduction needs to be investigated. If DensiProbe turned out to be an effective screening tool for patients with low bone strength that are on higher risk of the aforementioned complications these patients may in future benefit from alternative treatment methods (e.g. augmentation techniques) in order to reduce bone related fixation failure.

The primary aim of the present study is to investigate if bone strength measured by DensiProbeTM Hip (DensiProbe) is an independent factor to predict secondary loss of reduction (screw migration of 5 mm or more and / or telescoping of 10 mm or more) in patients with hip fractures after fracture fixation with DHS.


Eligibility criteria: Inclusion Criteria:

* Patients 50 years or older
* Patients with trochanteric or femoral neck fractures, classified as: AO 31-A1, AO 31-A2, AO 31-A3, AO 31-B1, AO 31-B2, AO 31-B3
* Patients undergoing fixation with DHS (135° aiming device, anti-rotational K-wire)
* Patients willing to participate in the study according to the clinical investigation plan
* Patients able to understand and read country national language at an elementary level
* Signed written informed consent by the patient or legal guardian

Exclusion Criteria:

* Bilateral hip fractures (at present or in the past)
* Open hip fracture
* Any previous surgical procedures of the hip (ipsilateral / contralateral)
* More than 7 days between injury and surgery
* Polytrauma (multiple injuries, whereof one or the combination of several injuries is life-threatening)
* Patients being pregnant or breast-feeding
* Pathologic fractures
* Active malignancy
* Psychiatric disorders that would preclude reliable assessment (e.g. severe depression)
* Drug or alcohol abuse
* Patients having participated in any other device or drug related clinical trial within the previous month

Primary outcomes:
measure: Migration of the screw in relation to the femoral head of 5 mm or more and/or Telescoping (shortening of the femoral neck) of 10 mm or more
timeFrame: 3 months
Secondary outcomes:
measure: Rate of complications
timeFrame: 3 months
measure: BMD values measured by DXA (contralateral hip)
timeFrame: Post OP
measure: Parker mobility score
timeFrame: 3 months
Other outcomes:
Locations:
city: Innsbruck
country: Austria
facility: Medizinische Universität
city: Wien
country: Austria
facility: Wilhelminenspital
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
city: Jena
country: Germany
facility: Friedrich-Schiller Universität
city: Münster
country: Germany
facility: Universitätsklinikum Münster
city: Almelo
country: Netherlands
facility: Twenteborg Ziekenhuis Almelo
city: Basel
country: Switzerland
facility: Universitätsspital
state: BS
city: Zürich
country: Switzerland
facility: Stadtspital Triemli
Study officials:
affiliation: Universitätsspital Basel
name: Norbert Suhm, MD
role: PRINCIPAL_INVESTIGATOR
References: